Is Akoya Biosciences, Inc. (AKYA) a Buy, Sell, or Hold?
NASDAQ : AKYA
Akoya Biosciences, Inc.
$1.29 USD
-$0.07 (-5.15%)
- Volume
- 715.25K
- Average Volume
- 582.12K
- Market Capitalization
- $64.44M
- P/E Ratio
- -1.15
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $3.42
- Year Low
- $0.93
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.61
Insider Activity Summary (Last 12 Months)
Insiders Buying
9
Insiders Selling
71
Amount of Insider Selling
$22.27M
AKYA Insider Buying/Selling by Quarter
AKYA Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Mendel Scott | director | 2025-07-08 | J-Other | 5.7 | 2025-07-10 |
| Mendel Scott | director | 2025-07-08 | J-Other | 2.01 | 2025-07-10 |
| Mendel Scott | director | 2025-07-08 | J-Other | 2.68 | 2025-07-10 |
| Mendel Scott | director | 2025-07-08 | J-Other | 19.94 | 2025-07-10 |
| Mendel Scott | director | 2025-07-08 | J-Other | 11.24 | 2025-07-10 |
| Mendel Scott | director | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | J-Other | 0 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | F-InKind | 0 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | J-Other | 0.9087 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | J-Other | 11.88 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | J-Other | 12.3 | 2025-07-10 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-07-08 | J-Other | 5.35 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 0 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | F-InKind | 0 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 0 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 16.12 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 0.3029 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 11.88 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 12.3 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 0.4427 | 2025-07-10 |
| McKelligon Brian | director, officer: President and CEO | 2025-07-08 | J-Other | 5.35 | 2025-07-10 |
| Kamocsay Jennifer | officer: Chief Legal Officer | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Kamocsay Jennifer | officer: Chief Legal Officer | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Kamocsay Jennifer | officer: Chief Legal Officer | 2025-07-08 | J-Other | 7.6 | 2025-07-10 |
| Kamocsay Jennifer | officer: Chief Legal Officer | 2025-07-08 | J-Other | 5.35 | 2025-07-10 |
| Ek John Frederick | officer: CFO | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Ek John Frederick | officer: CFO | 2025-07-08 | J-Other | 7.6 | 2025-07-10 |
| Ek John Frederick | officer: CFO | 2025-07-08 | J-Other | 5.35 | 2025-07-10 |
| Ek John Frederick | officer: CFO | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-07-08 | J-Other | 5.35 | 2025-07-10 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-07-08 | J-Other | 13.34 | 2025-07-10 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-07-08 | J-Other | 12.3 | 2025-07-10 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-07-08 | J-Other | 5.96 | 2025-07-10 |
| Winkler Matthew | director | 2025-07-08 | J-Other | 11.24 | 2025-07-10 |
| Winkler Matthew | director | 2025-07-08 | J-Other | 2.01 | 2025-07-10 |
| Winkler Matthew | director | 2025-07-08 | J-Other | 5.7 | 2025-07-10 |
| Winkler Matthew | director | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Winkler Matthew | director | 2025-07-08 | J-Other | 21.95 | 2025-07-10 |
| SHEPLER ROBERT G | director | 2025-07-08 | J-Other | 21.95 | 2025-07-10 |
| SHEPLER ROBERT G | director | 2025-07-08 | J-Other | 11.24 | 2025-07-10 |
| SHEPLER ROBERT G | director | 2025-07-08 | J-Other | 5.7 | 2025-07-10 |
| SHEPLER ROBERT G | director | 2025-07-08 | J-Other | 2.01 | 2025-07-10 |
| SCHNETTLER THOMAS P | director | 2025-07-08 | J-Other | 5.7 | 2025-07-10 |
| SCHNETTLER THOMAS P | director | 2025-07-08 | J-Other | 21.95 | 2025-07-10 |
| SCHNETTLER THOMAS P | director | 2025-07-08 | J-Other | 11.24 | 2025-07-10 |
| SCHNETTLER THOMAS P | director | 2025-07-08 | J-Other | 2.01 | 2025-07-10 |
| Raffin Thomas A. | director | 2025-07-08 | J-Other | 21.95 | 2025-07-10 |
| Raffin Thomas A. | director | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| Raffin Thomas A. | director | 2025-07-08 | J-Other | 11.24 | 2025-07-10 |
| Raffin Thomas A. | director | 2025-07-08 | J-Other | 5.7 | 2025-07-10 |
| Raffin Thomas A. | director | 2025-07-08 | J-Other | 2.01 | 2025-07-10 |
| LAI GOLDMAN MYLA | director | 2025-07-08 | J-Other | 0.38 | 2025-07-10 |
| LAI GOLDMAN MYLA | director | 2025-07-08 | J-Other | 11.24 | 2025-07-10 |
| LAI GOLDMAN MYLA | director | 2025-07-08 | J-Other | 18.1 | 2025-07-10 |
| LAI GOLDMAN MYLA | director | 2025-07-08 | J-Other | 2.01 | 2025-07-10 |
| LAI GOLDMAN MYLA | director | 2025-07-08 | J-Other | 5.7 | 2025-07-10 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-06-01 | F-InKind | 1.25 | 2025-06-02 |
| Ek John Frederick | officer: CFO | 2025-04-01 | F-InKind | 1.35 | 2025-04-03 |
| McKelligon Brian | director, officer: President and CEO | 2025-03-23 | F-InKind | 1.7 | 2025-03-25 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-03-23 | F-InKind | 1.7 | 2025-03-25 |
| Kamocsay Jennifer | officer: Chief Legal Officer | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| Kamocsay Jennifer | officer: Chief Legal Officer | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| Ek John Frederick | officer: CFO | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| McKelligon Brian | director, officer: President and CEO | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| McKelligon Brian | director, officer: President and CEO | 2025-03-01 | F-InKind | 1.63 | 2025-03-04 |
| Kamocsay Jennifer | officer: Chief Legal Officer | 2024-11-19 | A-Award | 0 | 2024-11-21 |
| Ek John Frederick | officer: CFO | 2024-11-19 | A-Award | 0 | 2024-11-21 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2024-11-19 | A-Award | 0 | 2024-11-21 |
| Ramachandran Niro Ph.D | officer: Chief Business Officer | 2024-11-19 | A-Award | 0 | 2024-11-21 |
| McKelligon Brian | director, officer: President and CEO | 2024-11-19 | A-Award | 0 | 2024-11-21 |
| Mendel Scott | director | 2024-10-02 | A-Award | 2.68 | 2024-10-04 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2024-08-29 | A-Award | 0 | 2024-09-03 |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2024-08-29 | 0 | 2024-09-03 | |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2024-08-29 | 5.96 | 2024-09-03 | |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2024-08-29 | 5.35 | 2024-09-03 | |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2024-08-29 | 13.34 | 2024-09-03 | |
| BAMFORD PASCAL | officer: Chief Clinical Officer | 2024-08-29 | 12.3 | 2024-09-03 | |
| McKelligon Brian | director, officer: President and CEO | 2024-06-11 | M-Exempt | 0.303 | 2024-06-12 |
| McKelligon Brian | director, officer: President and CEO | 2024-06-11 | M-Exempt | 0.303 | 2024-06-12 |
| McKelligon Brian | director, officer: President and CEO | 2024-06-11 | S-Sale | 2.084 | 2024-06-12 |
| McKelligon Brian | director, officer: President and CEO | 2024-06-06 | M-Exempt | 0.303 | 2024-06-07 |
| McKelligon Brian | director, officer: President and CEO | 2024-06-06 | M-Exempt | 0.303 | 2024-06-07 |
| McKelligon Brian | director, officer: President and CEO | 2024-06-06 | S-Sale | 2.0085 | 2024-06-07 |
| Raffin Thomas A. | director | 2024-06-04 | A-Award | 2.01 | 2024-06-05 |
| SHEPLER ROBERT G | director | 2024-06-04 | A-Award | 2.01 | 2024-06-05 |
| Winkler Matthew | director | 2024-06-04 | A-Award | 2.01 | 2024-06-05 |
| SCHNETTLER THOMAS P | director | 2024-06-04 | A-Award | 2.01 | 2024-06-05 |
| LAI GOLDMAN MYLA | director | 2024-06-04 | A-Award | 2.01 | 2024-06-05 |
| Mendel Scott | director | 2024-06-04 | A-Award | 2.01 | 2024-06-05 |
| Ek John Frederick | officer: CFO | 2024-04-01 | F-InKind | 4.56 | 2024-04-02 |
| Pla Frederic | officer: Chief Operating Officer | 2024-03-23 | F-InKind | 4.79 | 2024-03-25 |